UK – NICE rejects Lilly’s Verzenios for advanced breast cancer

The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of advanced breast cancer patients.

Lilly had been seeking a recommendation within Verzenios’ marketing authorisation, for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in adults who have had endocrine therapy.

NICE has reviewed additional evidence, collected as part of the Cancer Drugs Fund (CDF) managed access agreement for Verzenios plus fulvestrant in these breast cancer patients, to make this appraisal.

Typically, people with hormone receptor-positive, HER2-negative advanced breast cancer receive exemestane plus everolimus after endocrine therapy…